Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:55:36.838Z.
Calculation as of: 2026-10-06T19:55:36.838Z.
Quote observation: 2026-10-06T19:55:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 397c5a59cd83d044dab6d82224f034cfcc72b23d5b6e8de026e21d37d80d55f6
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$204.95M
PE Ratio
N/A
TTM Avg
399.45
3Y Avg
399.45
5Y Avg
399.45
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $199.29M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $199.21M | N/A | 5.74 | 5.74 | 5.74 |
| Exagen Inc. (XGN)vs › | $198.84M | N/A | N/A | N/A | N/A |
| Surrozen, Inc. (SRZN)vs › | $195.80M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $204.95M | N/A | 399.45 | 399.45 | 399.45 |
| RxSight, Inc. (RXST)vs › | $192.89M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.72M | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.42M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.44M | 15.85 | 14.32 | 17.96 | 17.40 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.68M | N/A | 8.07 | 11.31 | 11.31 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.79
Forward EPS (Est.)
$-0.86
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2022-11-08 | 22.00 |
| 2022-11-07 | 21.62 |
| 2022-11-04 | 21.23 |
| 2022-11-03 | 22.08 |
| 2022-11-02 | 23.13 |
| 2022-11-01 | 23.82 |
| 2022-10-31 | 23.59 |
| 2022-10-28 | 24.41 |
| 2022-10-27 | 23.00 |
| 2022-10-26 | 23.36 |
| 2022-10-25 | 23.15 |
| 2022-10-24 | 22.41 |
| 2022-10-21 | 22.77 |
| 2022-10-20 | 22.44 |
| 2022-10-19 | 22.82 |
| 2022-10-18 | 23.59 |
| 2022-10-17 | 23.87 |
| 2022-10-14 | 21.90 |
| 2022-10-13 | 22.85 |
| 2022-10-12 | 22.77 |
| 2022-10-11 | 23.05 |
| 2022-10-10 | 22.08 |
| 2022-10-07 | 22.26 |
| 2022-10-06 | 23.41 |
| 2022-10-05 | 23.69 |
| 2022-10-04 | 24.49 |
| 2022-10-03 | 23.90 |
| 2022-09-30 | 24.26 |
| 2022-09-29 | 24.23 |
| 2022-09-28 | 24.33 |
| 2022-09-27 | 21.77 |
| 2022-09-26 | 21.00 |
| 2022-09-23 | 21.62 |
| 2022-09-22 | 22.54 |
| 2022-09-21 | 22.87 |
| 2022-09-20 | 23.77 |
| 2022-09-19 | 24.03 |
| 2022-09-16 | 23.67 |
| 2022-09-15 | 25.15 |
| 2022-09-14 | 24.82 |
| 2022-09-13 | 23.69 |
| 2022-09-12 | 26.08 |
| 2022-09-09 | 24.68 |
| 2022-09-08 | 28.18 |
| 2022-09-07 | 27.49 |
| 2022-09-06 | 25.38 |
| 2022-09-02 | 26.82 |
| 2022-09-01 | 27.62 |
| 2022-08-31 | 26.54 |
| 2022-08-30 | 27.18 |
| 2022-08-29 | 27.21 |
| 2022-08-26 | 27.74 |
| 2022-08-25 | 29.62 |
| 2022-08-24 | 29.56 |
| 2022-08-23 | 29.31 |
| 2022-08-22 | 29.00 |
| 2022-08-19 | 29.77 |
| 2022-08-18 | 30.46 |
| 2022-08-17 | 30.33 |
| 2022-08-16 | 31.46 |
| 2022-08-15 | 33.05 |
| 2022-08-12 | 33.85 |
| 2022-08-11 | 32.46 |
| 2022-08-10 | 33.33 |
| 2022-08-09 | 32.46 |
| 2022-08-08 | 33.64 |
| 2022-08-05 | 33.49 |
